Vincent J. Milano has succeeded Michel de Rosen as president and chief executive officer of ViroPharma Incorporated (Exton, PA) and has been elected to its board of directors, effective March 31, 2008.
Vincent J. Milano has succeeded Michel de Rosen as president and chief executive officer of ViroPharma Incorporated (Exton, PA) and has been elected to its board of directors, effective March 31, 2008. De Rosen, who has led the company as president and chief executive officer since 2000, will continue as non-executive chairman of the board of directors. Milano joined ViroPharma in 1996. Since 2006, he has served as vice president, chief financial officer and chief operating officer. Prior to joining ViroPharma, Milano was with KPMG LLP, independent certified public accountants.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.